Signals in Motion: Pain, Metabolism & Terry’s Corner

Dr. GPCR News
Jun 24
2 min read

Hello GPCR Innovators,

We’re preparing to launch Terry’s Corner, a new knowledge hub shaped by Dr. Terry Kenakin’s decades of GPCR insight. It will bridge foundational receptor theory with today’s most pressing pharmacological questions, from biased signaling to allosteric design.

Meanwhile, incretin and amylin-based therapies are reshaping the obesity drug landscape. Novo Nordisk’s amycretin showed up to 24% weight loss, CagriSema delivered 22.7% in Phase 3, and semaglutide’s Canadian patent expiry is opening competitive pathways. Eli Lilly’s next moves with Orforglipron and its amylin analog are highly anticipated.

Plus, Celtarys explores ligand selection for better assays, and co-founder Dr. Maria Majellaro shares her story of innovation and listening-driven science.

This week’s publication highlights:

CXCR4 takes on a nuclear role in red blood cell maturation
CXCL13/CXCR5 emerges as a high-potential pain target
ST171, a biased 5‑HT1A agonist, delivers selective pain relief in preclinical models

Dr.GPCR Updates

Terry’s Corner – Build Better GPCR Screens with Dr. Kenakin

Four decades of receptor theory now fit in one expert-guided hub. Terry’s Corner gives you timeless and timely tools to improve selectivity, model efficacy, and design smarter GPCR pharmacology screens, anchored in real-world lessons and cutting-edge science.

Sign Up for The Kenakin Brief

Fluorescent Ligands vs. Radioligands – Assay Smarter

Celtarys explores how fluorescent ligands enable safer, high-throughput screening with rich kinetic data. Learn how these tools help retain assay integrity while eliminating radioactivity—perfect for next-gen GPCR workflows.

Upgrade Your Screening Strategy

Leadership in Ligand Design – The Celtarys Origin Story

In this founder interview, Dr. Maria Majellaro reveals how Celtarys evolved from a vision into a company solving real-world assay problems. It’s a story of leadership, scientific rigor, and tools built for the needs of modern discovery teams.

Read Maria’s Story

GPCR Publication Highlights

CXCR4 signaling promotes terminal erythropoiesis through nuclear translocation and perinuclear calcium bursts.
Blocking this chemokine axis reduces pain hypersensitivity by dampening neuroinflammation and glial activation.
This novel agonist activates Gi/o selectively, avoiding β-arrestin and showing strong pain relief in preclinical models.